← All trials
NCT03269994
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2017
- Primary completion
- Aug 28, 2019
- Completion date
- Aug 28, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- Advocate Illinois Masonic Medical CenterCollaborator
- Albany Medical CollegeCollaborator
- Baptist Memorial Health Care CorporationCollaborator
- Baylor Scott and WhiteCollaborator
- East Carolina UniversityCollaborator
- Emory UniversityCollaborator
- Temple UniversityCollaborator
- Gundersen Health SystemCollaborator
- Hackensack University Medical CenterCollaborator
- Indiana UniversityCollaborator
- Hackensack University Medical CenterCollaborator
- Johns Hopkins UniversityCollaborator
- Harvard UniversityCollaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- Pennsylvania State UniversityCollaborator
- Yeshiva UniversityCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
- Northwestern UniversityCollaborator
- Providence Health & ServicesCollaborator
- Rhode Island HospitalCollaborator
- Stony Brook UniversityCollaborator
- Temple UniversityCollaborator
- The Cleveland ClinicCollaborator
- Ohio State UniversityCollaborator
- University of OttawaCollaborator
- Thomas Jefferson UniversityCollaborator
- University of California, DavisCollaborator
- University of ChicagoCollaborator
- University of IowaCollaborator
- The University of Texas, DallasCollaborator
- University of UtahCollaborator
- University of WisconsinCollaborator
- Washington University in St. LouisCollaborator
- Memorial Sloan-Kettering Cancer CenterOfficial
- Allegiance HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.